Ding-Jie Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ding-Jie Lee has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Chin-Sheng Lin
Tri‐Service General Hospital, National Defense Medical University
2 shared publications - Shih-Hua Lin
Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical University, Taiwan
2 shared publications - Sy-Jou Chen
Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan
2 shared publications - Chia-Chao Wu
Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 114202, Taiwan
1 shared publication - Chia-Cheng Lee
Planning and Management Office, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
1 shared publication Chia-Hua Lin
Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
1 shared publication
Latest Publications
- Open Access
- 2 July 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (4)
DriverOmicsNet: an integrated graph convolutional network for multi-omics exploration of cancer driver genes
Cancer is a complex and heterogeneous group of diseases driven by genetic mutations and molecular changes. Identifying and characterizing cancer driver gene is crucial for understanding cancer biology and guiding precision oncology. Integrating multi-omics data can reveal the intricate molecular interactions underlying cancer progression and treatment responses. We developed a graph convolutional network (GCN) framework, DriverOmicsNet, that integrates multi-omics data using STRING protein–protein interaction networks and correlation-based weighted gene correlation network analysis (WGCNA). We applied this framework to 15 cancer types, analyzing 5555 tumor samples to predict cancer-related features such as homologous recombination deficiency, cancer stemness, immune clusters, tumor stage, and survival outcomes. DriverOmicsNet demonstrated superior predictive accuracy and model performance metrics across all target labels when compared with GCN models based on STRING network alone. Gene expression emerged as the most significant feature, reflecting the dynamic and functional state of cancer cells. The combined use of STRING PPI and WGCNA networks enhanced the identification of key driver genes and their interactions. Our study highlights the effectiveness of using GCNs to integrate multi-omics data for precision oncology. The integration of STRING PPI and WGCNA networks provides a comprehensive framework that improves predictive power and facilitates the understanding of cancer biology, paving the way for more tailored treatments.
- 2 July 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (4)
Open AccessDriverOmicsNet: an integrated graph convolutional network for multi-omics exploration of cancer driver genes
Cancer is a complex and heterogeneous group of diseases driven by genetic mutations and molecular changes. Identifying and characterizing cancer driver gene is crucial for understanding cancer biology and guiding precision oncology. Integrating multi-omics data can reveal the intricate molecular interactions underlying cancer progression and treatment responses. We developed a graph convolutional network (GCN) framework, DriverOmicsNet, that integrates multi-omics data using STRING protein–protein interaction networks and correlation-based weighted gene correlation network analysis (WGCNA). We applied this framework to 15 cancer types, analyzing 5555 tumor samples to predict cancer-related features such as homologous recombination deficiency, cancer stemness, immune clusters, tumor stage, and survival outcomes. DriverOmicsNet demonstrated superior predictive accuracy and model performance metrics across all target labels when compared with GCN models based on STRING network alone. Gene expression emerged as the most significant feature, reflecting the dynamic and functional state of cancer cells. The combined use of STRING PPI and WGCNA networks enhanced the identification of key driver genes and their interactions. Our study highlights the effectiveness of using GCNs to integrate multi-omics data for precision oncology. The integration of STRING PPI and WGCNA networks provides a comprehensive framework that improves predictive power and facilitates the understanding of cancer biology, paving the way for more tailored treatments.
- Open Access
- 8 April 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (4) , sfaf092
Monitoring serum potassium concentration in patients with severe hyperkalemia: the role of bloodless artificial intelligence-enabled electrocardiography
Background: Severe hyperkalemia is a life-threatening emergency requiring prompt management and close surveillance. Although artificial intelligence-enabled electrocardiography (AI-ECG) has been developed to rapidly detect hyperkalemia, its application to monitor potassium (K+) levels remains unassessed. This study aimed to evaluate the effectiveness of AI-ECG for monitoring K+ levels in patients with severe hyperkalemia. Methods: This retrospective study was performed at an emergency department of a single medical center over 2.5 years. Patients with severe hyperkalemia defined as Lab-K+ ≥6.5 mmol/l with matched ECG-K+ ≥5.5 mmol/l were included. ECG-K+ was quantified by ECG12Net analysis of the AI-ECG system. The following paired ECG-K+ and Lab-K+ were measured at least twice, almost simultaneously, during and after K+-lowering therapy in 1 day. Clinical characteristics, pertinent intervention, and laboratory data were analyzed. Results: Seventy-six patients fulfilling the inclusion criteria exhibited initial Lab-K+ 7.4 ± 0.7 and ECG-K+ 6.8 ± 0.5 mmol/l. Most of them had chronic kidney disease (CKD) or were on chronic hemodialysis (HD). The followed Lab-K+ and ECG-K+ measured with a mean time difference of 11.4 ± 5.6 minutes significantly declined in parallel both in patients treated medically (n = 39) and with HD (n = 37). However, there was greater decrement in Lab-K⁺ (mean 7.3 to 4.1) than ECG-K⁺ (mean 6.6 to 5.0) shortly after HD. Three patients with persistent ECG-K+ hyperkalemia despite normalized Lab-K+ exhibited concomitant acute cardiovascular comorbidities. Conclusions: AI-ECG for K+ prediction may help monitor K+ level for severe hyperkalemia and reveal more severe cardiac disorders in the patients with persistent AI-ECG hyperkalemia.
- 8 April 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (4) , sfaf092
Open AccessMonitoring serum potassium concentration in patients with severe hyperkalemia: the role of bloodless artificial intelligence-enabled electrocardiography
Background: Severe hyperkalemia is a life-threatening emergency requiring prompt management and close surveillance. Although artificial intelligence-enabled electrocardiography (AI-ECG) has been developed to rapidly detect hyperkalemia, its application to monitor potassium (K+) levels remains unassessed. This study aimed to evaluate the effectiveness of AI-ECG for monitoring K+ levels in patients with severe hyperkalemia. Methods: This retrospective study was performed at an emergency department of a single medical center over 2.5 years. Patients with severe hyperkalemia defined as Lab-K+ ≥6.5 mmol/l with matched ECG-K+ ≥5.5 mmol/l were included. ECG-K+ was quantified by ECG12Net analysis of the AI-ECG system. The following paired ECG-K+ and Lab-K+ were measured at least twice, almost simultaneously, during and after K+-lowering therapy in 1 day. Clinical characteristics, pertinent intervention, and laboratory data were analyzed. Results: Seventy-six patients fulfilling the inclusion criteria exhibited initial Lab-K+ 7.4 ± 0.7 and ECG-K+ 6.8 ± 0.5 mmol/l. Most of them had chronic kidney disease (CKD) or were on chronic hemodialysis (HD). The followed Lab-K+ and ECG-K+ measured with a mean time difference of 11.4 ± 5.6 minutes significantly declined in parallel both in patients treated medically (n = 39) and with HD (n = 37). However, there was greater decrement in Lab-K⁺ (mean 7.3 to 4.1) than ECG-K⁺ (mean 6.6 to 5.0) shortly after HD. Three patients with persistent ECG-K+ hyperkalemia despite normalized Lab-K+ exhibited concomitant acute cardiovascular comorbidities. Conclusions: AI-ECG for K+ prediction may help monitor K+ level for severe hyperkalemia and reveal more severe cardiac disorders in the patients with persistent AI-ECG hyperkalemia.
- 20 April 2022
- Published by Elsevier in Kidney International
- Vol. 101 (5) , 1091
Doxorubicin-associated red-colored dialysate
- 20 April 2022
- Published by Elsevier in Kidney International
- Vol. 101 (5) , 1091
Doxorubicin-associated red-colored dialysate
- Open Access
- 29 June 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (9) , bvab120
Artificial Intelligence–Assisted Electrocardiography for Early Diagnosis of Thyrotoxic Periodic Paralysis
Context Thyrotoxic periodic paralysis (TPP) characterized by acute weakness, hypokalemia, and hyperthyroidism is a medical emergency with a great challenge in early diagnosis since most TPP patients do not have overt symptoms. Objective This work aims to assess artificial intelligence (AI)-assisted electrocardiography (ECG) combined with routine laboratory data in the early diagnosis of TPP. Methods A deep learning model (DLM) based on ECG12Net, an 82-layer convolutional neural network, was constructed to detect hypokalemia and hyperthyroidism. The development cohort consisted of 39 ECGs from patients with TPP and 502 ECGs of hypokalemic controls; the validation cohort consisted of 11 ECGs of TPP patients and 36 ECGs of non-TPP individuals with weakness. The AI-ECG–based TPP diagnostic process was then consecutively evaluated in 22 male patients with TTP-like features. Results In the validation cohort, the DLM-based ECG system detected all cases of hypokalemia in TPP patients with a mean absolute error of 0.26 mEq/L and diagnosed TPP with an area under curve (AUC) of approximately 80%, surpassing the best standard ECG parameter (AUC = 0.7285 for the QR interval). Combining the AI predictions with the estimated glomerular filtration rate and serum chloride boosted the diagnostic accuracy of the algorithm to AUC 0.986. In the prospective study, the integrated AI and routine laboratory diagnostic system had a PPV of 100% and F-measure of 87.5%. Conclusion An AI-ECG system reliably identifies hypokalemia in patients with paralysis, and integration with routine blood chemistries provides valuable decision support for the early diagnosis of TPP.
- 29 June 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (9) , bvab120
Open AccessArtificial Intelligence–Assisted Electrocardiography for Early Diagnosis of Thyrotoxic Periodic Paralysis
Context Thyrotoxic periodic paralysis (TPP) characterized by acute weakness, hypokalemia, and hyperthyroidism is a medical emergency with a great challenge in early diagnosis since most TPP patients do not have overt symptoms. Objective This work aims to assess artificial intelligence (AI)-assisted electrocardiography (ECG) combined with routine laboratory data in the early diagnosis of TPP. Methods A deep learning model (DLM) based on ECG12Net, an 82-layer convolutional neural network, was constructed to detect hypokalemia and hyperthyroidism. The development cohort consisted of 39 ECGs from patients with TPP and 502 ECGs of hypokalemic controls; the validation cohort consisted of 11 ECGs of TPP patients and 36 ECGs of non-TPP individuals with weakness. The AI-ECG–based TPP diagnostic process was then consecutively evaluated in 22 male patients with TTP-like features. Results In the validation cohort, the DLM-based ECG system detected all cases of hypokalemia in TPP patients with a mean absolute error of 0.26 mEq/L and diagnosed TPP with an area under curve (AUC) of approximately 80%, surpassing the best standard ECG parameter (AUC = 0.7285 for the QR interval). Combining the AI predictions with the estimated glomerular filtration rate and serum chloride boosted the diagnostic accuracy of the algorithm to AUC 0.986. In the prospective study, the integrated AI and routine laboratory diagnostic system had a PPV of 100% and F-measure of 87.5%. Conclusion An AI-ECG system reliably identifies hypokalemia in patients with paralysis, and integration with routine blood chemistries provides valuable decision support for the early diagnosis of TPP.
- 23 December 2020
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 114 (2) , 136
Myxoedema in Hashimoto’s thyroiditis
- 23 December 2020
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 114 (2) , 136
Myxoedema in Hashimoto’s thyroiditis
Cryptic clues for an infection puzzle: from inside out
A 60-year-old male farmer with headache without fever for 2 months and with no other systemic disease presented to the emergency department with a 2-week history of non-productive cough as well as progressive hearing and vision loss. Chest radiography and CT scan revealed a left solitary tumour with pleural attachment (figure 1) without associated lymphadenopathy. At 3 days after admission, he lost consciousness and was administered emergency endotracheal …
Cryptic clues for an infection puzzle: from inside out
A 60-year-old male farmer with headache without fever for 2 months and with no other systemic disease presented to the emergency department with a 2-week history of non-productive cough as well as progressive hearing and vision loss. Chest radiography and CT scan revealed a left solitary tumour with pleural attachment (figure 1) without associated lymphadenopathy. At 3 days after admission, he lost consciousness and was administered emergency endotracheal …